Impact BioMedical Inc. (IBO) stock
IBONYSEPharmaceutical PreparationsFiscal year ends December 31
$3.06+0.38 (+14.18%)
Close on Oct 19, 2026Market cap $26.14MP/E –Yield –
Impact BioMedical operating margin
Operating margin is operating income as a percentage of revenue.
Impact BioMedical's operating margin for the twelve months ending Sep 30, 2026 was -12655.3%. For fiscal 2025 it was -13381.3%, against -6808.0% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -13381.3% | −6573.3 |
| FY2022 | Dec 31, 2022 | -6808.0% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -3085.7% | +2181.0 |
| Q2 FY2026 | Jun 30, 2026 | -23400.0% | −6928.6 |
| Q1 FY2026 | Mar 31, 2026 | -32700.0% | −31200.0 |
| Q4 FY2025 | Dec 31, 2025 | -16714.3% | – |
| Q3 FY2025 | Sep 30, 2025 | -5266.7% | – |
| Q2 FY2025 | Jun 30, 2025 | -16471.4% | – |
| Q2 FY2022 | Jun 30, 2022 | -1500.0% | – |
See a number that looks wrong?